紫杉醇脂质体联合卡铂治疗卵巢癌的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Paclitaxel Liposome combined with Carboplatin in the treatment of ovarian cancer. Methods A total of 60 cases of ovarian cancer treated in our hospital from January 2017 to June 2019 were selected as the resrarch objects, and they were divided into the control group and the observation group according to the random number table method, 30 cases in each group. The control group received Paclitaxel combined with Carboplatin treatment, the observation group received Paclitaxel Liposome combined with Carboplatin treatment. The short-term prognosis, side effects and quality of life at the end of treatment were compared between the two groups.Results There was no significant difference in the total effective rate between the two groups at the end of treatment(P＞0.05). The incidence of nausea, vomiting, fatigue, muscle pain and rash in the observation group were lower than those in the control group, the differences were statistically significant (P＜0.05). The scores of body function, role function, cognitive function, emotional function and social function in the observation group were higher than those in the control group, the differences were statistically significant (P＜0.05). Conclusion The efficacy of Paclitaxel Liposome is similar to that of Paclitaxel combined with Carboplatin in the treatment of ovarian cancer, but Paclitaxel Liposome has better safety and higher quality of life.

Key words： Ovarian cancer Paclitaxel Liposome Carboplatin Safety Quality of life

Received: 02 April 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/91

[1]	袁航，张远丽，张丽丽，等.2019年ESMO-ESGO 卵巢癌专家共识形成背景与框架要略[J].中国实用妇科与产科杂志，2019，35（8）：885-889.
[2]	郭俊英，廖沁园.卵巢癌的分子标志物及靶向治疗研究进展[J].世界最新医学信息文摘，2019，19（96）：88-89.
[3]	赖影.不同方法治疗卵巢癌的效果及对患者生存质量的影响比较[J].中国当代医药，2020，27（2）：110-113.
[4]	张色华，张月华.紫杉醇脂质体和传统紫杉醇治疗卵巢癌的效果研究[J].中国处方药，2019，17（11）：71-72.
[5]	Winner KK，Steinkamp MP，Lee RJ，et al.Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer[J].Cancer Res，2016，76（6）：1320-1334.
[6]	胡彩平，林毅，李秋萍.SF-36 量表与QLQ-C30 量表在老年癌症病人生活质量评估中的应用及其相关性研究[J].护理研究，2015，29（24）：2968-2972.
[7]	刘丽丽，朱丽娜，郑雅宁.卵巢癌病人生活质量现状调查及影响因素分析[J].全科护理，2019，17（17）：2054-2057.
[8]	杨定英，肖雁冰，涂皎，等.化疗方案选择对卵巢癌复发的影响研究[J].现代仪器与医疗，2018，24（5）：74-76.
[9]	具玲玲.对比紫杉醇脂质体与传统紫杉醇联合卡铂用于卵巢癌的效果及不良反应分析[J].中外女性健康研究，2019，（2）：111-112.
[10]	韩玲玲，胡欢.二甲双胍联合卡铂治疗治疗卵巢癌恶性发展患者的疗效[J].实用妇科内分泌电子杂志，2019，6（22）：85-86.
[11]	李思文，张燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息，2019，32（7）：150-152.
[12]	唐慕菲，朱余兵，李杨，等.紫杉醇脂质体与紫杉醇分别联合卡铂治疗卵巢癌疗效的Meta 分析[J].中国药师，2018，21（4）：657-661.
[13]	汪宝桩，孟光兴.紫杉醇及其脂质体治疗卵巢癌疗效与安全性Meta 分析[J].中国药业，2019，28（2）：73-78.
[14]	张新丽.紫杉醇脂质体联合奈达铂对Ⅲc、Ⅳ期卵巢癌患者的影响[J].实用中西医结合临床，2019，19（7）：97-98.
[15]	李彩霞.注射用紫杉醇脂质体联合奈达铂对晚期卵巢癌患者血清肿瘤标志物及免疫功能的影响[J].中国卫生工程学，2019，18（3）：455-457